Integra LifeSciences (NASDAQ:IART) Shares Gap Up to $33.52

Integra LifeSciences Holdings Co. (NASDAQ:IART) gapped up before the market opened on Wednesday . The stock had previously closed at $33.52, but opened at $34.80. Integra LifeSciences shares last traded at $33.81, with a volume of 16,652 shares changing hands.

Wall Street Analysts Forecast Growth

IART has been the topic of several analyst reports. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price on the stock in a research report on Wednesday. JMP Securities lowered their target price on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research report on Thursday, February 29th. StockNews.com downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Truist Financial lowered their price objective on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $44.89.

Integra LifeSciences Stock Down 0.3 %

The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. The company has a market capitalization of $2.66 billion, a PE ratio of 40.72, a P/E/G ratio of 1.01 and a beta of 1.12. The business has a 50-day moving average of $38.70 and a 200 day moving average of $39.52.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The firm had revenue of $397.00 million during the quarter, compared to analysts’ expectations of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. Integra LifeSciences’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.94 earnings per share. Equities research analysts predict that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC increased its stake in Integra LifeSciences by 248.5% during the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after acquiring an additional 415 shares during the last quarter. Hexagon Capital Partners LLC grew its stake in shares of Integra LifeSciences by 123.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock valued at $29,000 after buying an additional 370 shares during the last quarter. Itau Unibanco Holding S.A. grew its stake in shares of Integra LifeSciences by 469.5% during the second quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock valued at $31,000 after buying an additional 615 shares during the last quarter. Gladius Capital Management LP bought a new position in shares of Integra LifeSciences during the third quarter valued at approximately $47,000. Finally, Covestor Ltd grew its stake in shares of Integra LifeSciences by 82.5% during the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after buying an additional 921 shares during the last quarter. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.